OTLK - Outlook Therapeutics

Small biotech with high tight flag after FDA revisit; he exited but expects another run.

Already up 100% in 2.5 weeks, recommend taking profits on half to two-thirds due to news-driven risk.

The host references OTLK as a previous successful biotech play he recommended, noting it gained 150% (from $0.74 to $1.79) after a similar FDA catalyst. He does not give a current recommendation on OTLK, only using it as a historical example of potential gains from such setups.

Previously recommended stock now up 130-140% from $80 entry to $180. Ross suggests considering partial profits at current levels near $180-$200 resistance zone. Still may keep going but profit-taking advised.

The FDA reversed its previous rejection after a formal appeal, and a final approval decision is expected within 60 days. The stock could double or triple from current levels if approval is granted. The stock already quadrupled in 12 days on the reversal news and is now consolidating in a flag pattern rather than selling off, suggesting further upside potential.

Ross presents OTLK as a high-upside catalyst trade with an FDA decision expected within 60 days. He notes the drug is already approved in Europe, the FDA itself admitted the evidence is there, and the stock could double or triple on approval. He is actively setting up TradingView alerts and buy stop orders for the breakout.